What is KeyCorp’s Estimate for IDXX Q3 Earnings?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) – KeyCorp issued their Q3 2026 earnings per share estimates for shares of IDEXX Laboratories in a report released on Sunday, October 11th. KeyCorp analyst S. Dechert anticipates that the company will earn $3.70 per share for the quarter. KeyCorp currently has a “Sector Weight” rating on the stock. The consensus estimate for IDEXX Laboratories’ current full-year earnings is $14.81 per share. KeyCorp also issued estimates for IDEXX Laboratories’ Q4 2026 earnings at $3.34 EPS, FY2026 earnings at $14.77 EPS, Q1 2027 earnings at $3.93 EPS, Q2 2027 earnings at $4.61 EPS, Q3 2027 earnings at $4.22 EPS, Q4 2027 earnings at $3.81 EPS, FY2027 earnings at $16.58 EPS and FY2028 earnings at $18.74 EPS.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS.

IDXX has been the subject of several other research reports. Citigroup boosted their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. UBS Group increased their price target on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Finally, Barclays lowered their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Six equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $747.00.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $520.31 on Wednesday. The firm has a market cap of $40.99 billion, a P/E ratio of 36.85, a P/E/G ratio of 2.80 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. IDEXX Laboratories has a 1-year low of $500.61 and a 1-year high of $769.98. The firm has a fifty day moving average of $536.72 and a two-hundred day moving average of $552.17.

Hedge Funds Weigh In On IDEXX Laboratories

A number of hedge funds have recently added to or reduced their stakes in the business. J. Stern & Co. LLP lifted its holdings in IDEXX Laboratories by 23,694.7% in the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after purchasing an additional 2,642,200 shares during the period. Bank of New York Mellon Corp bought a new position in IDEXX Laboratories in the 2nd quarter valued at about $628,223,000. Arrowstreet Capital Limited Partnership increased its stake in IDEXX Laboratories by 52.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock valued at $471,335,000 after buying an additional 288,471 shares during the period. Alyeska Investment Group L.P. increased its stake in IDEXX Laboratories by 97.3% during the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock valued at $211,146,000 after buying an additional 197,808 shares during the period. Finally, Montrusco Bolton Investments Inc. increased its stake in IDEXX Laboratories by 93.4% during the 1st quarter. Montrusco Bolton Investments Inc. now owns 342,120 shares of the company’s stock valued at $186,707,000 after buying an additional 165,188 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the sale, the director directly owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.79% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.